Ardy Arianpour is CEO & Co-Founder of SEQSTER, the leading healthcare technology company that puts the patient at the center of all their health data. He is a visionary health tech executive with 20+ years driving innovation in life sciences, pharma and digital health.

SEQSTER was founded in 2016 in San Diego with the mission of positively impacting patient lives at scale by removing the barriers to health data access. Prior to starting SEQSTER, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics, and served as SVP of Ambry Genetics, which sold to Konica in 2017 for $1 Billion. As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardy played an instrumental role in scaling genetic testing access with the launch of BRCA testing benefiting patients and family members across the country.

Ardy received his BS in Biological Sciences from UC Irvine and an MBA from Marshall Goldsmith School of Management. He has been recognized with many awards, such as a Top 40 Healthcare Transformer by Medical, Marketing, and Media (MM&M), San Diego Business Journal's 40 under 40, COX Top Tech Awards, SD500 Most Influential Leaders, Top 10 Pioneers Redefining Healthcare in 2021, Med Tech World Rising Star 2022, and PharmaVOICE 100 Inspiring Leaders in Life Sciences 2023. Ardy is Faculty for NextMed.Health, Judge at Top Tech Awards, on the Digital Health Advisory Board of UCSD, Inside Precision Medicine Advisory Board, and the Board of Trustees of Fleet Science Center.